このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Jacobio Pharmaceuticals Group 過去の業績

過去基準チェック /06

Jacobio Pharmaceuticals Groupは17.7%の年平均成長率で業績を伸ばしているが、Biotechs業界はgrowingで11.7%毎年増加している。売上は減少しており、年平均3.9%の割合である。

主要情報

17.7%

収益成長率

40.2%

EPS成長率

Biotechs 業界の成長	11.0%
収益成長率	-3.9%
株主資本利益率	-33.5%
ネット・マージン	-565.4%
前回の決算情報	31 Dec 2023

Recent updates

Most Shareholders Will Probably Agree With Jacobio Pharmaceuticals Group Co., Ltd.'s (HKG:1167) CEO Compensation

May 31

Is Jacobio Pharmaceuticals Group (HKG:1167) Using Debt Sensibly?

May 29

We're Hopeful That Jacobio Pharmaceuticals Group (HKG:1167) Will Use Its Cash Wisely

May 10

Time To Worry? Analysts Are Downgrading Their Jacobio Pharmaceuticals Group Co., Ltd. (HKG:1167) Outlook

Aug 26

We're Not Very Worried About Jacobio Pharmaceuticals Group's (HKG:1167) Cash Burn Rate

Jul 29

We Think Jacobio Pharmaceuticals Group (HKG:1167) Can Afford To Drive Business Growth

Apr 29

What Percentage Of Jacobio Pharmaceuticals Group Co., Ltd. (HKG:1167) Shares Do Insiders Own?

Mar 21

収支内訳

Jacobio Pharmaceuticals Group の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

SEHK:1167 収益、費用、利益 ( )CNY Millions
日付	収益	収益	G+A経費	研究開発費
31 Dec 23	64	-359	47	372
30 Sep 23	72	-385	45	420
30 Jun 23	81	-410	43	468
31 Mar 23	89	-391	43	457
31 Dec 22	96	-372	43	446
30 Sep 22	123	-332	46	391
30 Jun 22	150	-292	49	336
31 Mar 22	151	-297	47	308
31 Dec 21	153	-301	45	281
30 Sep 21	348	-570	52	259
30 Jun 21	544	-839	60	237
31 Mar 21	515	-1,177	57	211
31 Dec 20	486	-1,514	54	186
30 Sep 20	243	-1,298	65	171
30 Jun 20	0	-1,082	77	156
31 Mar 20	0	-753	74	147
31 Dec 19	0	-425	71	139

質の高い収益: 1167は現在利益が出ていません。

利益率の向上: 1167は現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: 1167は利益を出していないが、過去 5 年間で年間17.7%の割合で損失を削減してきた。

成長の加速: 1167の過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: 1167は利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 22.1% ) と比較することは困難です。

株主資本利益率

高いROE: 1167は現在利益が出ていないため、自己資本利益率 ( -33.46% ) はマイナスです。

Jacobio Pharmaceuticals Group 過去の業績

過去 基準チェック /06

主要情報

最近の業績更新

Full year 2023 earnings released: CN¥0.46 loss per share (vs CN¥0.49 loss in FY 2022)

Jacobio Pharmaceuticals Group Co., Ltd. to Report Fiscal Year 2023 Results on Mar 28, 2024

First half 2023 earnings released: CN¥0.22 loss per share (vs CN¥0.17 loss in 1H 2022)

Jacobio Pharmaceuticals Group Co., Ltd. to Report First Half, 2023 Results on Aug 30, 2023

Full year 2022 earnings released: CN¥0.49 loss per share (vs CN¥0.40 loss in FY 2021)

Jacobio Pharmaceuticals Group Co., Ltd. to Report First Half, 2022 Results on Aug 23, 2022

Recent updates

Jacobio Pharmaceuticals Group Co., Ltd. (SEHK:1167) commences an Equity Buyback Plan for 79,175,508 shares, representing 10% of its issued share capital, under the authorization approved on June 7, 2024.

Most Shareholders Will Probably Agree With Jacobio Pharmaceuticals Group Co., Ltd.'s (HKG:1167) CEO Compensation

Is Jacobio Pharmaceuticals Group (HKG:1167) Using Debt Sensibly?

Jacobio Pharmaceuticals Group Co., Ltd. Receives Approval of Registrational Phase III Clinical Trial of Glecirasib (Jab-21822) and Epidermal Growth Factor Receptor Inhibitor Erbitux in Patients with Colorectal Cancer

Jacobio Pharma Announces Its KRAS G12C Inhibitor Reached the Primary Endpoint

Jacobio Pharma to Present Data of PARP7 Inhibitor and P53 Reactivator at the 2024 AACR Annual Meeting

Full year 2023 earnings released: CN¥0.46 loss per share (vs CN¥0.49 loss in FY 2022)

Jacobio Pharmaceuticals Group Co., Ltd., Annual General Meeting, Jun 07, 2024

Jacobio Pharmaceuticals Group Co., Ltd. to Report Fiscal Year 2023 Results on Mar 28, 2024

Jacobio Pharma Announces China CDE Clearance for Phase III Clinical Trial of SHP2 Inhibitor Plus KRAS G12C Inhibitor

Jacobio Pharma Presents Data of Glecirasib in Patients with Pancreatic Cancer and Other Solid Tumors At the 2024 ASCO GI

Jacobio Pharmaceuticals Group Co., Ltd. Announces Clinical Results in the Oral Abstract Session of Clinical Oncology Gastrointestinal Cancers Symposium

Jacobio Pharma Presents Clinical Results of Glecirasib in Combination with Jab-3312 At Esmo

Executive Chairman & CEO recently bought HK$594k worth of stock

First half 2023 earnings released: CN¥0.22 loss per share (vs CN¥0.17 loss in 1H 2022)

Jacobio Pharmaceuticals Group Co., Ltd. to Report First Half, 2023 Results on Aug 30, 2023

Jacobio Pharmaceuticals Group Co., Ltd.'S In-House KRAS G12C Inhibitor Jab-21822 (Glecirasib) Granted Breakthrough Therapy Designation for Pancreatic Cancer Patients

Jacobio Pharmaceuticals Group Co., Ltd. announced that it expects to receive CNY 150 million in funding from Beijing E-Town International Investment & Development Co., Ltd.

Consensus revenue estimates fall by 86%

Jacobio Pharmaceuticals Group Co., Ltd. Presents Clinical Results of Glecirasib in Colorectal Cancer

Jacobio Pharmaceuticals Group Co., Ltd. Receives Investigational New Drug (IND) Approval for PARP7 Inhibitor JAB-26766 in China

We're Hopeful That Jacobio Pharmaceuticals Group (HKG:1167) Will Use Its Cash Wisely

Full year 2022 earnings released: CN¥0.49 loss per share (vs CN¥0.40 loss in FY 2021)

Jacobio Pharma Completes First Patient Dosage of Aurora Inhibitor JAB-2485 in U.S

Jacobio's Kras G12c Inhibitor JAB-21822 Was Granted Breakthrough Therapy Designations by China Cde

Jacobio's Preclinical Results of KRAS G12C Inhibitor in Combination with SHP2 Inhibitor Will be Presented at the ESMO Asia Congress 2022

Less than half of directors are independent

Jacobio Receives CDE Approval for KRAS G12C Inhibitor JAB-218822's Phase II Pivotal Study in China

Jacobio Pharma Completes First Patient Dosage of Cd73 Mab Jab-Bx102 in China

Jacobio Pharmaceuticals Group Co., Ltd. Announces First Patient Dosed with JAB-21822 in the Phase IIa Trial on KRAS G12C and STK11 Co-Mutation

Consensus revenue estimates fall by 12%

Time To Worry? Analysts Are Downgrading Their Jacobio Pharmaceuticals Group Co., Ltd. (HKG:1167) Outlook

Jacobio Pharmaceuticals Group Co., Ltd. Announces Change of Joint Company Secretary

Jacobio Pharmaceuticals Group Co., Ltd. to Report First Half, 2022 Results on Aug 23, 2022

We're Not Very Worried About Jacobio Pharmaceuticals Group's (HKG:1167) Cash Burn Rate

Jacobio Pharma will Present Phase I Clinical Data of KRAS G12C Inhibitor JAB-21822 at the 2022 ASCO Annual Meeting

We Think Jacobio Pharmaceuticals Group (HKG:1167) Can Afford To Drive Business Growth

Less than half of directors are independent

Board Member recently bought HK$91k worth of stock

Senior VP & Executive Director recently bought HK$150k worth of stock

Senior VP & Executive Director recently bought HK$336k worth of stock

Jacobio Pharmaceuticals Group Co., Ltd. JAB-21822 in Combination with Cetuximab Completes First Dose of Colorectal Cancer Patient in China

Senior VP & Executive Director recently bought HK$1.6m worth of stock

Jacobio Pharmaceuticals Group Co., Ltd. Announces Investigational New Drug Approval of Aurora A Inhibitor JAB-2485 from Food and Drug Administration of the United States

Jacobio Pharma Receives IND Approval for Combination Therapy of KRAS G12C and Cetuximab Injection in China

Jacobio Announces First Patient Dosed in Phase I/II Clinical Trial of Kras G12c Inhibitor for Solid Tumor

Jacobio Announces First Two Patients Dosed in SHP2 Combination Study, Triggering $20 Million Milestone Payment

Jacobio Announces FDA Approves IND Application to Develop KRAS G12c Inhibitor

Joint Company Secretary has left the company

What Percentage Of Jacobio Pharmaceuticals Group Co., Ltd. (HKG:1167) Shares Do Insiders Own?

Jacobio Pharmaceuticals Group Co., Ltd. to Report Fiscal Year 2020 Results on Mar 26, 2021

Jacobio Pharmaceuticals Group Co., Ltd. Together with Its Subsidiaries Receive Two Investigational New Drug (The "IND") Approvals to Initiate Clinical Trials for Its Shp2 Inhibitors

Jacobio Pharmaceuticals Group Co., Ltd. has completed an IPO in the amount of HKD 1.350665 billion.

収支内訳

収益と収入の歴史

フリー・キャッシュフローと収益の比較

過去の収益成長分析

株主資本利益率

総資産利益率

使用総資本利益率

過去の好業績企業の発掘

過去基準チェック /06